MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/20.06.25 Share Price

Warrant

DE000ME9ZN49

Real-time Bid/Ask 16:02:05 01/07/2024 BST
0.34 EUR / 0.35 EUR +4.55% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/20.06.25
Current month+46.67%
1 month+47.98%
Date Price Change
01/07/24 0.29 -12.12%
28/06/24 0.33 0.00%
27/06/24 0.33 -2.94%
26/06/24 0.34 -8.11%
25/06/24 0.37 +23.33%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 02:19 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME9ZN4
ISINDE000ME9ZN49
Date issued 11/03/2024
Strike 220 $
Maturity 20/06/2025 (354 Days)
Parity 10 : 1
Emission price 0.55
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.49
Lowest since issue 0.189
Delta0.16x
Omega 6.635
Premium55.06x
Gearing41.33x
Moneyness 0.6551
Difference Strike 74.51 $
Difference Strike %+33.87%
Spread 0.01
Spread %3.03%
Theoretical value 0.3250
Implied Volatility 33.39 %
Total Loss Probability 90.58 %
Intrinsic value 0.000000
Present value 0.3250
Break even 223.49 €
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus